EASTERN COOPERATIVE ONCOLOGY GROUP

Summary

Principal Investigator: Joseph Sparano
Affiliation: Montefiore Medical Center
Country: USA
Abstract: This application is submitted by the Albert Einstein College of Medicine (AECOM) in order to request funding via the U10 mechanism to continue as a main institutional member of the Eastern Cooperative Oncology Group (ECOG). AECOM faculty plays key roles scientific and administrative leadership roles in ECOG, including both clinical and translational research. The AECOM Cancer Center (AECC) is an NCI-designated Cancer Center that has been continuously funded since 1971. During the last 3-year grant cycle, AECC members accrued approximately 150 patients to ECOG therapeutic trials, authored or co-authored 17 manuscripts and 17 abstracts related to ECOG studies, chaired or co-chaired 7 ECOG studies that were completed or developed, and played key roles as study chair or co-chair in two pivotal breast cancer trials that were orally presented at the 2005 American Society of Clinical Oncology meeting (E2197) and 2005 San Antonio Breast Cancer Symposium (E1199). AECOM faculty provided scientific leadership in the breast (J. Sparano), gastrointestinal (L. Rajdev), leukemia (R. Gallagher, A. Melnick, A. Verma), lymphoma (J. Sparano), head/neck (M. Haigentz), developmental therapeutics (S. Mani), and thoracic committees (S. Keller, R. Perez-Soler). Moreover, AECOM faculty have played key roles in supporting ECOG's translational research, as evidenced by Dr. Robert Gallagher's role as a promeylocytic leukemia core laboratory director (NIH 5RO1-CA65771), and the recent recruitment of Dr. Ari Melnick to serve as chair of the Leukemia Laboratory Committee. During the next funding period, AECOM investigators will play key roles as study chairs or co-chairs for studies in breast (TAILORx, E1104) and gastrointestinal (E3205, E3206) cancers, and leukemia (E1905). The principal investigator of this application (J. Sparano) also plays a key administrative role in ECOG as an ECOG Executive Committee member, ECOG Associate Chair for Disease and Modality Research, and founder and program director for the annual ECOG Young Investigator Symposium. Approximately 70% of patients enrolled on ECOG studies are minorities, evidence of an effective program for recruitment of minority subjects. Finally, the recent creation of the Montefiore-Einstein Cancer Center Network (MECCN) is projected to result in up to a 50% increase in accrual during the next funding period by facilitating the participation of AECOM-affiliated community physicians.
Funding Period: 1978-06-01 - 2010-04-30
more information: NIH RePORT

Top Publications

  1. ncbi Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993)
    Janice P Dutcher
    Albert Einstein College NY, Bronx, NY, USA
    Leuk Lymphoma 46:377-85. 2005
  2. ncbi Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with >20 years follow-up
    Peter H Wiernik
    Montefiore Medical Center North Division, Cancer Center, New York Medical College, Bronx, NY 10466, USA
    Leuk Lymphoma 50:1632-41. 2009
  3. pmc Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197
    Lori J Goldstein
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:4092-9. 2008
  4. pmc Weekly paclitaxel in the adjuvant treatment of breast cancer
    Joseph A Sparano
    Eastern Cooperative Oncology Group, Philadelphia, USA
    N Engl J Med 358:1663-71. 2008
  5. ncbi Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group
    Hossein Borghaei
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Immunother 30:455-67. 2007
  6. ncbi A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia
    Mark R Litzow
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St S W, Rochester, MN 55905, USA
    Haematologica 91:1105-8. 2006
  7. ncbi Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282
    Minaxi Jhawer
    Department of Oncology, Montefiore Medical Center, Weiler Hospital, Room 2S 49, 1825 Eastchester Road, Bronx, NY 10461, USA
    Invest New Drugs 24:447-54. 2006
  8. ncbi Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease
    Doru T Alexandrescu
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, NY 10446, USA
    Leuk Lymphoma 47:641-56. 2006
  9. ncbi Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196
    Stanley Zucker
    Veterans Affairs Medical Center, Northport, NY State University Hospital of New York, Stony Brook, USA
    Clin Breast Cancer 6:525-9. 2006
  10. pmc Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317
    Michael S Gordon
    Premiere Oncology of Arizona, Scottsdale, AZ 85260, USA
    J Clin Oncol 27:5788-93. 2009

Scientific Experts

Detail Information

Publications10

  1. ncbi Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993)
    Janice P Dutcher
    Albert Einstein College NY, Bronx, NY, USA
    Leuk Lymphoma 46:377-85. 2005
    ..Combination therapy with other differentiating agents may be useful in this disease...
  2. ncbi Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with >20 years follow-up
    Peter H Wiernik
    Montefiore Medical Center North Division, Cancer Center, New York Medical College, Bronx, NY 10466, USA
    Leuk Lymphoma 50:1632-41. 2009
    ..002). Treatment toxicity was acceptable. After MOPP-Bleo induction for advanced Hodgkin lymphoma, ABVD provides better consolidation than local RT...
  3. pmc Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197
    Lori J Goldstein
    Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 26:4092-9. 2008
    ..The purpose of this trial was to determine whether adjuvant AT improved disease-free survival compared with AC in operable breast cancer...
  4. pmc Weekly paclitaxel in the adjuvant treatment of breast cancer
    Joseph A Sparano
    Eastern Cooperative Oncology Group, Philadelphia, USA
    N Engl J Med 358:1663-71. 2008
    ..We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer...
  5. ncbi Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group
    Hossein Borghaei
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Immunother 30:455-67. 2007
    ..Here, we report the results of E3194, a phase 1B/2 trial conducted by the Eastern Cooperative Oncology Group that employed 2B1 therapy in 20 women with metastatic breast cancer. The median age was 51 years...
  6. ncbi A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia
    Mark R Litzow
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St S W, Rochester, MN 55905, USA
    Haematologica 91:1105-8. 2006
    ..One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL...
  7. ncbi Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282
    Minaxi Jhawer
    Department of Oncology, Montefiore Medical Center, Weiler Hospital, Room 2S 49, 1825 Eastchester Road, Bronx, NY 10461, USA
    Invest New Drugs 24:447-54. 2006
    ..This regimen and sequence is worthy of further study especially in combination with colony stimulating factors, however, its tolerability may be most applicable for patients who have had minimal prior therapy...
  8. ncbi Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease
    Doru T Alexandrescu
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, NY 10446, USA
    Leuk Lymphoma 47:641-56. 2006
    ..Although significant, the toxicities associated with this regimen were manageable...
  9. ncbi Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196
    Stanley Zucker
    Veterans Affairs Medical Center, Northport, NY State University Hospital of New York, Stony Brook, USA
    Clin Breast Cancer 6:525-9. 2006
    ....
  10. pmc Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317
    Michael S Gordon
    Premiere Oncology of Arizona, Scottsdale, AZ 85260, USA
    J Clin Oncol 27:5788-93. 2009
    ..In this trial, we evaluated the efficacy of erlotinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor in patients with advanced pRCC, a tumor type associated with wild-type von Hippel Lindau gene...